These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1680483)

  • 1. Apomorphine lowers dopamine synthesis for up to 48 h: implications for drug sensitization.
    Rodriguez M; Castro R
    Neuroreport; 1991 Jul; 2(7):365-8. PubMed ID: 1680483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of GBR 12909 on locomotor activity and dopamine turnover in mice: comparison with apomorphine.
    Irifune M; Nomoto M; Fukuda T
    Eur J Pharmacol; 1995 Jan; 272(1):79-85. PubMed ID: 7713153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of apomorphine on in vivo release of dopamine and its metabolites in the prefrontal cortex and the striatum, studied by a microdialysis method.
    Ozaki N; Nakahara D; Miura H; Kasahara Y; Nagatsu T
    J Neurochem; 1989 Dec; 53(6):1861-4. PubMed ID: 2809596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurochemical and behavioral effects of acute and chronic treatment with apomorphine in rats.
    Rowlett JK; Mattingly BA; Bardo MT
    Neuropharmacology; 1991 Feb; 30(2):191-7. PubMed ID: 1903190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurotensin counteracts apomorphine-induced inhibition of dopamine release as studied by microdialysis in rat neostriatum.
    Tanganelli S; von Euler G; Fuxe K; Agnati LF; Ungerstedt U
    Brain Res; 1989 Nov; 502(2):319-24. PubMed ID: 2819469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic transplants normalize amphetamine- and apomorphine-induced Fos expression in the 6-hydroxydopamine-lesioned striatum.
    Cenci MA; Kalén P; Mandel RJ; Wictorin K; Björklund A
    Neuroscience; 1992; 46(4):943-57. PubMed ID: 1347413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
    Yuan H; Sarre S; Ebinger G; Michotte Y
    Brain Res; 2004 Nov; 1026(1):95-107. PubMed ID: 15476701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic L-dopa treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance.
    Carey RJ
    Brain Res; 1991 Dec; 568(1-2):205-14. PubMed ID: 1814568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of changes in locomotor activity with striatal homovanillic acid and 3,4-dihydroxyphenylacetic acid concentrations following the bilateral intranigral injection of dopamine agonist drugs in rats.
    Kelly E; Jenner P; Marsden CD
    J Pharm Pharmacol; 1987 Mar; 39(3):196-202. PubMed ID: 2883284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of repeated treatment with high doses of selegiline on behaviour, striatal dopaminergic transmission and tyrosine hydroxylase mRNA levels.
    Themann C; Alvarez Fischer D; Gross S; Westermann R; Weihe E; Kuschinsky K; Schäfer H; Ferger B
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Jan; 365(1):22-8. PubMed ID: 11862330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatal dopamine receptor sensitivity after subchronic fencamfamine in the rat.
    Scavone C; De Lucia R; Bernardi MM; Aizenstein ML
    Eur J Pharmacol; 1985 May; 112(1):11-6. PubMed ID: 4040467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of apomorphine-induced conditioned place preference in rats co-injected with buspirone: relationship with serotonin and dopamine in the striatum.
    Haleem DJ; Ikram H; Haleem MA
    Brain Res; 2014 Oct; 1586():73-82. PubMed ID: 25160128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent, hydroxyl radical-scavenging effect of apomorphine with iron and dopamine perfusion in rat striatum.
    Chen YK; Lin HC; Liu JC; Wan FJ
    Brain Res; 2001 Mar; 896(1-2):165-8. PubMed ID: 11277987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine receptor antagonism by the novel antianxiety drug, buspirone.
    McMillen BA; Matthews RT; Sanghera MK; Shepard PD; German DC
    J Neurosci; 1983 Apr; 3(4):733-8. PubMed ID: 6131948
    [No Abstract]   [Full Text] [Related]  

  • 15. Striatal dopamine metabolism in response to apomorphine: the effects of repeated amphetamine pretreatment.
    Kuczenski R; Leith NJ; Applegate CD
    Brain Res; 1983 Jan; 258(2):333-7. PubMed ID: 6824917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine-synthesis and tyrosine-hydroxylase are regulated by independent DA-receptor mediated mechanisms.
    Tissari HA; Porceddu ML; Argiolas A; Di Chiara G; Gessa GL
    Life Sci; 1978 Aug; 23(6):653-8. PubMed ID: 29202
    [No Abstract]   [Full Text] [Related]  

  • 17. Apomorphine enantiomers' effects on dopamine metabolism: receptor and non-receptor related actions.
    Saller CF; Salama AI
    Eur J Pharmacol; 1986 Feb; 121(2):181-8. PubMed ID: 3699091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurochemical correlates of behavioral sensitization following repeated apomorphine treatment: assessment of the role of D1 dopamine receptor stimulation.
    Rowlett JK; Mattingly BA; Bardo MT
    Synapse; 1993 Jun; 14(2):160-8. PubMed ID: 8332946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conditioning of behavioural effects produced by an intermediate dose of apomorphine: hypokinesia, ptosis and stereotypies.
    Nowak K; Kuschinsky K
    Naunyn Schmiedebergs Arch Pharmacol; 1987 Sep; 336(3):262-6. PubMed ID: 3683596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further investigations into the relationship between the dopaminergic system, ascorbic acid and uric acid in the rat striatum.
    Desole MS; Miele M; Esposito G; Enrico P; Fresu L; De Natale G; Miele E
    Eur J Pharmacol; 1991 Nov; 205(1):97-100. PubMed ID: 1812002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.